Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Freeman-Keller, Morganna, Kim, Youngchul, Cronin, Heather, Richards, Allison, Gibney, Geoffrey, Weber, Jeffrey S.·2016·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-15-1136

Cited by (860)

Items 401–500 of 860

Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor
Sousuke Kubo, Nobuaki Kobayashi, Kohei Somekawa, Momo Hirata, Chisato Kamimaki, Hiroko Aiko, Seigo Katakura, Shuhei Teranishi, Keisuke Watanabe, Yu Hara et al. · 2020 · Anticancer Research
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients
Mette-Triin Purde, Rebekka Niederer, Nikolaus Benjamin Wagner, Stefan Diem, Fiamma Berner, Omar Hasan Ali, Dorothea Hillmann, Irina Bergamin, Markus Joerger, Martin Risch et al. · 2021 · Journal of Cancer Research and Clinical Oncology
Real-World Prevalence and Tolerability of Immune-Related Adverse Events in Older Adults with Non-Small Cell Lung Cancer: A Multi-Institutional Retrospective Study
Ryosuke Matsukane, Takahiro Oyama, Ryosuke Tatsuta, Sakiko Kimura, Kojiro Hata, Shuhei Urata, Hiroyuki A. Watanabe · 2024 · Cancers
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ke Ma, Qingqing Jin, Miao Wang, Xin Li, Yuyang Zhang · 2019 · Expert Review of Molecular Diagnostics
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab
Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim · 2019 · Scientific Reports
Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
Kana Ono, Hirotaka Ono, Yukihiro Toi, Jun Sugisaka, Mari Aso, Ryohei Saito, Sachiko Kawana, Tomoiki Aiba, Tetsuo Odaka, Suguru Matsuda et al. · 2021 · Cancer Medicine
Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Takafumi Yamamoto, Takanori Ito, Tetsunari Hase, Masatoshi Ishigami, Kazuyuki Mizuno, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Hirofumi Shibata et al. · 2021 · Cancer Investigation
Skin Reactions to Immune Checkpoint Inhibitors
Anisha B. Patel, Omar Pacha · 2018 · Advances in experimental medicine and biology
Vitiligo—Thyroid Disease Association: When, in Whom, and Why Should It Be Suspected? A Systematic Review
Ana Maria Chivu, Elena Bălăşescu, Larisa Pandia, Roxana Nedelcu, Alice Brînzea, Gabriela Turcu, Mihaela Antohe, Daniela Adriana Ion · 2022 · Journal of Personalized Medicine
The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?
Robin Reschke, Benjamin Deitert, Alexander Enk, Jessica C. Hassel · 2024 · Frontiers in Immunology
Skin Reactions to Immune Checkpoint Inhibitors
Anisha B. Patel, Omar Pacha · 2017 · Advances in experimental medicine and biology
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
Amr Menshawy, Abdelrahman A. Eltonob, Sarah A. Barkat, Ahmed K. Ghanem, Mahmoud M. Mniesy, Ishak Mohamed, Mohamed Abdel-Maboud, Omar Mohamed Mattar, Mohamed Elfil, Eshak I. Bahbah et al. · 2018 · Melanoma Research
Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma
Kotaro Suzuki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa · 2019 · Journal of Immunotherapy
Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?
Susanne Lütje, Georg Feldmann, Markus Essler, Peter Brossart, Ralph Alexander Bundschuh · 2020 · Journal of Nuclear Medicine
Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice
Elísabeth Pérez-Ruiz, Jerónimo Jiménez-Castro, Miguel‐Ángel Berciano‐Guerrero, Javier Valdivia, Sara Estalella-Mendoza, Fátima Toscano, María Rodríguez de la Borbolla Artacho, Margarita Garrido-Siles, María José Martínez Bautista, Rosa Villatoro Roldán et al. · 2020 · Clinical & Translational Oncology
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
Marta Dudzińska, Michał Szczyrek, Kamila Wojas‐Krawczyk, Joanna Świrska, Izabela Chmielewska, Agnieszka Zwolak · 2020 · Cancers
Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience.
Wei‐Fan Hsu, Po‐Heng Chuang, Cheng‐Kuo Chen, Hung‐Wei Wang, Ming-Hung Tsai, Wen‐Pang Su, Hung‐Yao Chen, Chi‐Ying Yang, Chun‐Che Lin, Guan‐Tarn Huang et al. · 2020 · PubMed Central
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandalà, James Larkin, Paolo A. Ascierto, Michele Del Vecchio, Helen J Gogas, Charles Lance Cowey, Ana Maria Arance, Stéphane Dalle, Michael Schenker, Jean‐Jacques Grob et al. · 2021 · Journal for ImmunoTherapy of Cancer
Immunotherapy Toxicity
Charlene M. Mantia, Elizabeth Iannotti Buchbinder · 2019 · Hematology/Oncology Clinics of North America
Immunotherapy Toxicities
Katherine G. Sanchez, David B. Page, Walter John Urba · 2019 · Surgical Oncology Clinics of North America
Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center
Rosaria Maddalena Ruggeri, Calogera Claudia Spagnolo, Angela Alibrandi, Nicola Silvestris, Salvatore Cannavò, Mariacarmela Santarpía · 2023 · Journal of Endocrinological Investigation
Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes
Ryosuke Matsukane, Kimitaka Suetsugu, Kojiro Hata, Keisuke Matsuda, Satoshi Nakao, Haruna Minami, Hiroyuki A. Watanabe, Takeshi Hirota, Nobuaki Egashira, Ichiro Ieiri · 2023 · International Journal of Clinical Oncology
PD-1/PD-L1 Inhibitors plus Chemotherapy Versus Chemotherapy Alone for Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Eric Pasqualotto, Francisco Cézar Aquino de Moraes, Matheus Pedrotti, Maria Eduarda Cavalcanti Souza, Anna Luíza Soares de Oliveira Rodrigues, Rafael Oliva Morgado Ferreira, Lucca Moreira Lopes, Artur Menegaz de Almeida, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos · 2023 · Cancers
Blockade of Programmed Cell Death Protein-1 Pathway for the Treatment of Melanoma
Madhuri Bhandaru, Anand Rotte · 2017 · Journal of Dermatologic Research And Therapy
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction
Kei Kunimasa, Taiki Isei, Harumi Nakamura, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Toru Kumagai, Shin‐ichi Nakatsuka, Hiroko Endo et al. · 2018 · Investigational New Drugs
The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis
Huilin Xu, Ximing Xu, Wei Ge, Jin-Ju Lei, Dedong Cao · 2020 · Therapeutic Advances in Medical Oncology
Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges
Bo Qiu, Cassie Kline, Sabine Mueller · 2021 · Frontiers in Oncology
Toxicités dermatologiques des inhibiteurs de checkpoint immunologiques
Vincent Sibaud, Serge Boulinguez, Cécile Pagès, L. Riffaud, Laurence Lamant, Ciprian Chira, Sabrina Boyrie, Émmanuelle Vigarios, É. Tournier, Nicolás Meyer · 2018 · Annales de Dermatologie et de Vénéréologie
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Małgorzata Bobrowicz, Radosław Zagożdżon, Joanna Domagała, Roberta Vasconcelos‐Berg, Emmanuella Guenova, Magdalena Winiarska · 2019 · Cancers
Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
Panagiota Economopoulou, Ioannis Kotsantis, George Papaxoinis, Niki Gavrielatou, Μaria Anastasiou, Anastasios Pantazopoulos, George Kavourakis, Stavros Gkolfinopoulos, Ioannis G. Panayiotides, Alexander Delides et al. · 2020 · Oral Oncology
Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases
Zhiya Xu, Huilan Li, Xinyi Yu, Jia Luo, Zanling Zhang · 2024 · Hematology
Dermatologic toxicities related to cancer immunotherapy
Yosra Vaez-Gharamaleki, Mohammad Amin Akbarzadeh, Farhad Jadidi‐Niaragh, Ata Mahmoodpoor, Sarvin Sanaie, Mohammad‐Salar Hosseini · 2025 · Toxicology Reports
Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
Qian Sun, Hongyan Sun, Nan Wu, Yue Hu, Fangqing Zhang, Xianling Cong · 2022 · Frontiers in Oncology
Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study
Nicola Hermann, Lara Valeska Maul, Milad Ameri, Stephan Traidl, Reihane Ziadlou, Karolina Papageorgiou, Isabel Kolm, Mitchell Paul Levesque, Julia‐Tatjana Maul, Marie‐Charlotte Brüggen · 2022 · Cancers
Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan
Hisashi Uhara · 2018 · International Journal of Clinical Oncology
Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors
Subashini Gnanendran, Lauren Maree Turner, James Austin Miller, Shelley Ji Eun Hwang, Andrew Charles Miller · 2020 · Current Treatment Options in Oncology
Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies
Alexandra Frelau, Xavier Palard-Novello, Eva Jali, Lise Boussemart, Alain Dupuy, Pandora James, Anne Devillers, Florence Le Jeune, Julien Edeline, Thierry Lesimple et al. · 2020 · Cancer Immunology Immunotherapy
Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
Lorena Villa-Crespo, Sebastián Podlipnik, Natàlia Anglada-Masferrer, Clara Izquierdo, Priscila Giavedoni, Pablo Iglesias, M. Zegarra Domínguez, Francisco Aya, Ana Maria Arance, Josep Malvehy et al. · 2022 · Cancers
Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma
Melissa S. Thebeau, Krista M. Rubin, Matthias Hofmann, Julia Grimm, Alyona Weinstein, Jennifer Nam Choi · 2017 · Journal of the American Association of Nurse Practitioners
An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer
Ken Naganuma, Yosuke Horita, Keisuke Matsuo, Yu Miyama, Yoshiaki Mihara, Masanori Yasuda, Shintaro Nakano, Tetsuya Hamaguchi · 2022 · Internal Medicine
Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors
Mariana Serino, Cláudia Freitas, M Martins, Pedro Magalhães Ferreira, Catarina Gouveia Cardoso, F. Veiga, Vanessa Santos, D. Araújo, Hélder Novais Bastos, A. Magalhães et al. · 2022 · Pulmonology
Melanoma antigens recognized by T cells and their use for immunotherapy
Shigeki Ohta, Aya Misawa, Chaw Kyi‐Tha‐Thu, Naomi Matsumoto, Yoshie Hirose, Yutaka Kawakami · 2023 · Experimental Dermatology
Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study
Jiän Zhang, Aiqin Gao, Shuyun Wang, Yanxin Sun, Jiake Wu, Dahai Wang, Yihui Ge, Juan Li, Haifeng Sun, Qinglei Cheng et al. · 2024 · Respiratory Research
Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 – Seasonal variation and association with outcome
Rebecca Schou Jurlander, Louise Mahncke Guldbrandt, Rikke Boedker Holmstroem, Kasper S Madsen, Marco Donia, Charlotte Aaquist Haslund, Henrik Schmidt, Lars Bastholt, Christina H. Bruvik Ruhlmann, Inge Marie Svane et al. · 2024 · European Journal of Cancer
Nivolumab-induced vitiligo successfully treated with narrowband UVB phototherapy
Takuya Miyagawa, Takafumi Kadono, Yuri Masui, Daisuke Yamada, Ryosuke Saigusa, Hiroko Numajiri, Jun Omatsu, Yoshihide Asano, Shinichi Sato · 2017 · European Journal of Dermatology
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors
Moshe Chaim Ornstein, Cassandra M. Calabrese, Laura S. Wood, Elizabeth Kirchner, Pam Profusek, Kimberly D Allman, Allison M. Martin, Apostolos Kontzias, Petros D. Grivas, Jorge Alberto Garcia et al. · 2019 · Clinical Genitourinary Cancer
Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma
Jingjing Zhao, Xizhi Wen, Ya Ding, Dandan Li, Baoyan Zhu, Jingjing Li, Desheng Weng, Xing Zhang, Xiaoshi Zhang · 2020 · Aging
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Jingjing Fan, Xiangfeng Shen, Yishu Wang, Honglan Zhou, Guolong Liu, Yulin Li, Zhi‐Xiang Xu · 2020 · Biomedicine & Pharmacotherapy
Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
Izabela Chmielewska, Marta Dudzińska, Michał Szczyrek, Joanna Świrska, Kamila Wojas‐Krawczyk, Agnieszka Zwolak · 2021 · PLoS ONE
Skin manifestations associated with checkpoint inhibitors
Gianluca Nazzaro, Stefano Buffon, Serena Giacalone, Carlo Alberto Maronese, Angelo Valerio Marzano · 2022 · JEADV Clinical Practice
Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient
Pooja H. Rambhia, Kord S. Honda, Joshua Arbesman · 2018 · Melanoma Research
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
Nicola Silvestris, Antonella Argentiero, Giordano Domenico Beretta, Paolo Di Bartolo, Monica Montagnani, Romano Danesi, Pietro Ferrari, Stella D’Oronzo, Stefania Gori, Antonio Dello Russo et al. · 2020 · Critical Reviews in Oncology/Hematology
Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival
Dennis McGonagle, Nicola Luigi Bragazzi, Howard Amital, ‬‬‬‬Abdulla Watad · 2019 · Autoimmunity Reviews
Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents
Cláudia Freitas, Maria Jacob, Nuno Tavares, Natália Alves Martins, Conceição Souto-Moura, David Araújo, Hélder Novais Bastos, Vanessa Santos, Gabriela Fernandes, Adriana Magalhães et al. · 2021 · Anti-Cancer Drugs
Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab
Kousuke Ueda, Shigetaka Suekane, Hirofumi Kurose, Naoki Ito, Naoyuki Ogasawara, Tasuku Hiroshige, Katsuaki Chikui, Kazuhisa Ejima, Keiichiro Uemura, Makoto Nakiri et al. · 2022 · Japanese Journal of Clinical Oncology
Hepatobiliary and Pancreatic Adverse Events
Hao Chi Zhang, Lan Sun Wang, Ethan Miller · 2021 · Advances in experimental medicine and biology
Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis
Fangmin Zhao, Junjing Zhu, Rui Yu, Tianyu Shao, Shuyi Chen, Gaochenxi Zhang, Qijin Shu · 2022 · Scientific Reports
Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus
Valérie Desmedt, Aranzazu Jauregui-Amezaga, Liselotte Fierens, Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, João Sabino, Lara Crapé, Michael J. G. Somers et al. · 2023 · European Journal of Cancer
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
Gregory E. Sanda, Julie M. Shabto, Subir Goyal, Yuan Liu, Dylan J. Martini, Bassel Nazha, Jacqueline Theresa Brown, Lauren Beth Yantorni, Greta Anne Russler, Sarah E. Caulfield et al. · 2023 · The Oncologist
Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study
Anne R. Bass, Fenglong Xie, Deanna Jannat‐Khah, Nilasha Ghosh, Karmela K Chan, Ashish Saxena, Jeffrey R. Curtis · 2024 · Lara D. Veeken
Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
Hamid Salim Shaaban, Sugabramya Kuru, Nazia Hasan Khan · 2017 · International Journal of Critical Illness and Injury Science
Checkpoint inhibitor-associated autoimmunity
Karim Ladak, Anne R. Bass · 2018 · Best Practice & Research Clinical Rheumatology
Immune checkpoint inhibitor‐induced vitiligo in advanced melanoma could be related to increased levels of CCL19
Taku Fujimura, Kayo Tanita, Y. Sato, Congmin Lyu, Yumi Kambayashi, Yasuhiro Fujisawa, Hiroshi Uchi, Yuki Yamamoto, Atsushi Otsuka, Kenji Yoshino et al. · 2019 · British Journal of Dermatology
Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors
Ryan G. Holstead, Baskoro Kartolo, Wilma M. Hopman, Tara D. Baetz · 2021 · Melanoma Research
Systemic Treatment of Cutaneous Adverse Events after Immune Checkpoint Inhibitor Therapy: A Review
Alexandria M. Brown, Wylie M. Masterson, Jonathan Lo, Anisha B. Patel · 2021 · Dermatitis
Drug eruptions with novel targeted therapies – immune checkpoint and EGFR inhibitors
Isabella Pospischil, Wolfram Hoetzenecker · 2021 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
A rare case of lung carcinoma acquires multidrug-resistant Klebsiella pneumoniae pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia
Chao Liu, Ling Ding, Yehan Zhu, Cheng Chen · 2017 · Therapeutics and Clinical Risk Management
Severe Oral Ulcers Associated With Nivolumab Treatment
Takeshi Namiki, Takaaki Hanafusa, Makiko Ueno, Keiko Miura, Hiroo Yokozeki · 2016 · JAMA Dermatology
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
Rebecca Karp Leaf, Jodi Victoria Mones, Tushar Shenoy, Mohamed Warsame, Marina Beltrami Moreira, Sandhya Panch, Andrew D. Leavitt, Rebecca L. Zon, Ellen K. Kendall, Sahar Shahamatdar et al. · 2025 · Blood
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy
Mingjia Li, Songzhu Zhao, Gabrielle Lopez, Austin Secor, Parthib Das, Nitya Surya, Madison M. Grogan, Sandip H. Patel, Karthik Chakravarthy, Abdul Miah et al. · 2023 · Cancer Immunology Immunotherapy
Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
Kerasia‐Maria Plachouri, Vaia Florou, Vasileios L. Georgiou, Sophia Georgiou · 2023 · Cancers
Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
Evan Rosenbaum P. E, Kenneth P. Seier, Martina Bradić, Ciara Marie Kelly, Sujana Movva, Benjamin Alexander Nacev, Mrinal M. Gounder, Mary Louise Keohan, Viswatej Avutu, Ping Chi et al. · 2023 · Cancer Research Communications
The application and mechanism of PD pathway blockade for cancer therapy
Xing Wang, Shan Huang, Ya Zhang, Lin Zhu, Xiaoliang Wu · 2017 · Postgraduate Medical Journal
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study
Melissa Bersanelli, Elisabetta Lattanzi, Nunziata D’Abbiero, Sebastiano Buti, Alessandro Leonetti, Maria Can�, Salvatore Trapani, Gianluca Gravina, Giampiero Porzio, Katia Cannita et al. · 2019 · Biomedical Reports
A review of the imaging manifestations of immune check point inhibitor toxicities
Richard Thomas, Bibin Sebastian, Tom George, Noor Fatima Majeed, Temilola Akinola, Shawn L. Laferriere, Marta Braschi‐Amirfarzan · 2020 · Clinical Imaging
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
Johanna Matull, Elisabeth Livingstone, Axel Wetter, Lisa Zimmer, Anne Zaremba, Harald Lahner, Dirk Schadendorf, Selma Ugurel · 2020 · Frontiers in Oncology
The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study
Taigo Kato, Akira Nagahara, Norihiko Kawamura, Wataru Nakata, Tetsuji Soda, Kyosuke Matsuzaki, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Ryoichi Imamura et al. · 2021 · International Journal of Clinical Oncology
Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab
Doran Ksienski, Pauline T. Truong, Nicole S. Croteau, Angela M. Y. Chan, Eric Sonke, Tiffany Patterson, Melissa Clarkson, Samuel Hackett, Mary Lesperance · 2021 · Journal of Geriatric Oncology
Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, YooHyun Song, Yoshifumi Hori, Toshihisa Tomoda, Mirii Harada, Shingo Tamura, Akihiro Miura et al. · 2022 · Cancer Management and Research
Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
Ye Tao, Xiang Li, Bing Liu, Jia Wang, Chao Lv, Shaolei Li, Yuzhao Wang, Jinfeng Chen, Shi Yan, Nan Wu · 2023 · Frontiers in Oncology
Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer
Wei Ye, Meiye Li, Ke-Wang Luo · 2023 · Pharmaceutics
Nivolumab-Induced Synchronous Occurrence of Myositis and Hypothyroidism in a Patient with Squamous Cell Lung Cancer
Sonja Badovinac, Marta Koršić, Kamelija Žarković, Davorka Muršić, M Roglić, Marko Jakopović, Miroslav Samaržija · 2018 · Immunotherapy
Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer
Hanae Ida, Yasushi Goto, Jun Sato, Shintaro Kanda, Yuki Shinno, Ryou Morita, Shuji Murakami, Yuji Matsumoto, Tatsuya Yoshida, Hidehito Horinouchi et al. · 2020 · Medical Oncology
Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab
John A. Cuenca, Andrés Laserna, María P. Reyes, Joseph L. Nates, Gregory H. Botz · 2020 · Case Reports in Critical Care
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
Andrea Botticelli, Silvia Mezi, Giulia Pomati, Paolo Sciattella, Bruna Cerbelli, Michela Roberto, Giulia Mammone, Alessio Cirillo, Alessandra Cassano, Carmela Di Dio et al. · 2020 · Vaccines
Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy
Camila Simões, Swan N. Thung, Maria Isabel Fiel, Max W. Sung, Myron Schwartz, Stephen C. Ward · 2020 · Modern Pathology
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
Alison Margaret Weppler, Andrew Pattison, Prachi Bhave, Paolo B. De Ieso, Jeanette Raleigh, Athena Hatzimihalis, Anthony James Gill, Shiva Balachander, Jason Callahan, Margaret S.-T. Chua et al. · 2020 · Journal for ImmunoTherapy of Cancer
Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital
Javier Torres-Jiménez, Jorge Esteban-Villarrubia, P. García‐Abellás, Alfonso Cortés-Salgado, Ainara Soria-Rivas, P. Gajate-Borau, Maria Eugenia Olmedo, E. Corral de la Fuente, Yolanda Lage, Ana Gómez‐Rueda et al. · 2021 · Clinical & Translational Oncology
Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
Yoshiyasu Kono, Yasuhiro Choda, Masahiro Marshall Nakagawa, Koji Miyahara, Michihiro Ishida, Tetsushi Kubota, Keiji Seo, Tetsu Hirata, Yuka Obayashi, Tatsuhiro Gotoda et al. · 2021 · Targeted Oncology
Causes of Pruritus in Patients Treated With Immune Checkpoint Inhibitors for Melanomas or Skin Carcinomas
Nadia Salinas, Emmanuel Nowak, M. Étienne, Délphine Legoupil, Maxime Fouchard, E. Brenaut, L. Misery · 2021 · Frontiers in Medicine
Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study
Hanna J. Lee, Anjali D Manavalan, Mihaela Stefan–Lifshitz, Clyde B. Schechter, Aloke Maity, Yaron Tomer · 2023 · Frontiers in Endocrinology
Nanotechnology‐enhanced radiotherapy and the abscopal effect: Current status and challenges of nanomaterial‐based radio‐immunotherapy
Dhushyanth Viswanath, Jeehun Park, Rahul Misra, Vincenzo J. Pizzuti, Sung‐Ho Shin, Junsang Doh, You‐Yeon Won · 2023 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
Tianhang Zhang, Haitao Lv, Jiasong Li, Shasha Zhang, Jingjing Zhang, Siqi Wang, Yingnan Wang, Zhanjun Guo · 2024 · Frontiers in Immunology
An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab
Matthew H. Lee, Nagashree Seetharamu · 2019 · Case Reports in Dermatological Medicine
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study
Alessio Cortellini, Sebastiano Buti, Melissa Bersanelli, Raffaele Giusti, Fabiana Perrone, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Antonino Grassadonia, Katia Cannita et al. · 2020 · OncoImmunology
Challenges faced when identifying patients for combination immunotherapy
Marc S. Ernstoff, Shipra Gandhi, Manu Raj Pandey, Igor J. Puzanov, Petros D. Grivas, Alberto J. Montero, Vamsidhar Velcheti, Mary Jo Turk, Claudia Marcela Diaz-Montero, Lionel D. Lewis et al. · 2017 · Future Oncology
Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma
Kenji D. Nakamura, Kazutoshi Okubo, Takeshi Takahashi, Kenji Mitsumori, Takashi Ishigaki, Hiroyuki Ohnishi · 2018 · IJU Case Reports
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
Kyung‐Ann Lee, Hae‐Rim Kim, So Young Yoon · 2019 · The Korean Journal of Internal Medicine
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
Yuh-Min Chen, James Chih‐Hsin Yang, Wu‐Chou Su, Inn‐Wen Chong, Te‐Chun Hsia, Meng-Chih Lin, Gee‐Chen Chang, Chao‐Hua Chiu, Chao‐Chi Ho, Shang‐Yin Wu et al. · 2020 · Journal of the Formosan Medical Association
Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events
Ryuji Yasumatsu, Mioko Matsuo, Takahiro Wakasaki, Muneyuki Masuda, Toranoshin Takeuchi, Tomomi Manako, Rina Jiromaru, Ryutaro Uchi, Kazuki Hashimoto, Takashi Nakagawa · 2020 · Acta Oto-Laryngologica